According to the Globocan 2020 report, liver cancer is the fourth most frequent cancer in Asia, with the region accounting for over 70% of all new liver cancer cases worldwide. Hepatocellular carcinoma (HCC) and bile duct malignancies are highly prevalent in Asia, especially in China and South Korea where the prevalence rate is about five times higher than in Western countries.
Novotech 贊助 2023 年北美生物科技產業展 (BIO 2023) 的亞太峰會,並贊助 Endpoints 舉辦關於與中國建立生物科技合作的討論會
美國 - 麻薩諸塞州波士頓 - Novotech 是亞太地區領先的生物科技受託研究機構 (CRO),為下列兩項活動提供贊助:
報告